Results 141 to 150 of about 1,085,795 (289)

THE FORMATION OF MACROGLOBULIN ANTIBODIES. II. STUDIES ON NEONATAL INFANTS AND OLDER CHILDREN* [PDF]

, 1962
Chester W. Fink, William E. Miller, Barbara Dorward, Joseph LoSpalluto   +3 more
openalex   +1 more source

HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases [PDF]

, 2023
Marthe Kirkesæther Brun, K. H. Bjørlykke, Marte K. Viken, Grethe‐Elisabeth Stenvik, Rolf Anton Klaasen, Johanna Elin Gehin, David J. Warren, Joseph Sexton, Øystein Sandanger, Tore K Kvien, Cato Mørk, Espen A. Haavardsholm, Jørgen Jahnsen, Guro Løvik Goll, Benedicte A. Lie, Nils Bolstad, Kristin Kaasen Jørgensen, Silje Watterdal Syversen   +17 more
openalex   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Experimental infection of inbred guinea pigs with Treponema pallidum: development of lesions and formation of antibodies. [PDF]

, 1985
Charles S. Pavia, C J Niederbuhl
openalex   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

A comprehensive lab cookbook for creating carbohydrate modified proteins for therapeutic applications

Frontiers in Pharmacology, 2013
Bibhash eMukhopadhyay
doaj   +1 more source

Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease. [PDF]

Drugs, 2021
Lenders M, Brand E.
europepmc   +1 more source

Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges [PDF]

, 2016
Emilie M.J. van Brummelen, Willeke Ros, Gertjan Wolbink, Jos H. Beijnen, Jan H.M. Schellens   +4 more
openalex   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department. [PDF]

J Transl Autoimmun, 2021
Guchelaar NAD, van Laar JAM, Hermans MAW, van der Houwen TB, Atmaca S, van Maaren MS, Brkic Z, van Daele PLA, Dalm VASH, van Hagen PM, Rombach SM.   +10 more
europepmc   +1 more source